Klaus Lücke
Geen lopende functies
Profiel
Klaus Lücke is the founder of GILUPI GmbH, which was founded in 2006.
He held the title of Chief Executive Officer from 2009 to 2012.
Dr. Lücke also worked as an Executive Director at Infineon Technologies AG, a Development Manager at Siemens AG, and a Principal at Bell Laboratories.
Dr. Lücke received his undergraduate degree from Freie Universität Berlin.
Eerdere bekende functies van Klaus Lücke
| Bedrijven | Functie | Einde |
|---|---|---|
| INFINEON TECHNOLOGIES AG | Directeur/Bestuurslid | - |
| SIEMENS AG | Corporate Officer/Principal | - |
Bell Laboratories
 Bell Laboratories Miscellaneous Commercial ServicesCommercial Services Bell Laboratories provides research and development services. It provides communications technologies including transistors, digital networking, signal processing, lasers and fiber-optic communications systems, communication satellites, cellular telephony, electronic switching of calls, touch-tone dialing and modems. The company was founded in 1925 and is headquartered in Murray Hill, NJ. | Corporate Officer/Principal | - |
GILUPI GmbH
 GILUPI GmbH Medical SpecialtiesHealth Technology GILUPI GmbH develops and produces products for the in-vivo isolation of rare cells from the circulation. Its product GILUPI CellCollector enables the detection of rare cells directly from the blood of patients. The company was founded by Klaus Lücke, Ulrich Pison, Michael Giersig, and Fabian Rüchardt in 2006 and is headquartered in Potsdam, Germany. | Algemeen Directeur | - |
Opleiding van Klaus Lücke
| Freie Universität Berlin | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SIEMENS AG | Producer Manufacturing |
| INFINEON TECHNOLOGIES AG | Electronic Technology |
| Bedrijven in privébezit | 2 |
|---|---|
GILUPI GmbH
GILUPI GmbH Medical SpecialtiesHealth Technology GILUPI GmbH develops and produces products for the in-vivo isolation of rare cells from the circulation. Its product GILUPI CellCollector enables the detection of rare cells directly from the blood of patients. The company was founded by Klaus Lücke, Ulrich Pison, Michael Giersig, and Fabian Rüchardt in 2006 and is headquartered in Potsdam, Germany. | Health Technology |
Bell Laboratories
Bell Laboratories Miscellaneous Commercial ServicesCommercial Services Bell Laboratories provides research and development services. It provides communications technologies including transistors, digital networking, signal processing, lasers and fiber-optic communications systems, communication satellites, cellular telephony, electronic switching of calls, touch-tone dialing and modems. The company was founded in 1925 and is headquartered in Murray Hill, NJ. | Commercial Services |
